Immuneering (NASDAQ:IMRX - Get Free Report) will likely be announcing its earnings results before the market opens on Friday, March 7th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter.
Immuneering Price Performance
Shares of NASDAQ IMRX traded down $0.16 during trading on Monday, reaching $1.50. 502,369 shares of the stock traded hands, compared to its average volume of 2,578,322. The company has a 50-day moving average of $1.99 and a 200-day moving average of $1.95. Immuneering has a 52-week low of $1.00 and a 52-week high of $7.68. The stock has a market capitalization of $46.42 million, a P/E ratio of -0.76 and a beta of -0.36.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on IMRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $12.00 target price on shares of Immuneering in a research note on Thursday, February 6th. Chardan Capital reiterated a "buy" rating and issued a $13.00 price objective on shares of Immuneering in a research note on Wednesday, January 8th. Finally, Morgan Stanley downgraded Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Immuneering has a consensus rating of "Hold" and an average target price of $12.20.
Read Our Latest Research Report on Immuneering
Immuneering Company Profile
(
Get Free Report)
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.
Recommended Stories
Before you consider Immuneering, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immuneering wasn't on the list.
While Immuneering currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
